293 related articles for article (PubMed ID: 25099612)
41. Association of 25-hydroxyvitamin D with areal and volumetric measures of bone mineral density and parathyroid hormone: impact of vitamin D-binding protein and its assays.
Jemielita TO; Leonard MB; Baker J; Sayed S; Zemel BS; Shults J; Herskovitz R; Denburg MR
Osteoporos Int; 2016 Feb; 27(2):617-26. PubMed ID: 26359185
[TBL] [Abstract][Full Text] [Related]
42. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
43. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).
Romanus D; Kindler HL; Archer L; Basch E; Niedzwiecki D; Weeks J; Schrag D;
J Pain Symptom Manage; 2012 Feb; 43(2):205-17. PubMed ID: 22104618
[TBL] [Abstract][Full Text] [Related]
44. Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States.
Crutchley RD; Gathe J; Mayberry C; Trieu A; Abughosh S; Garey KW
AIDS Res Hum Retroviruses; 2012 May; 28(5):454-9. PubMed ID: 21878055
[TBL] [Abstract][Full Text] [Related]
45. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy.
Ma K; Xu W; Wang C; Li B; Su K; Li W
Cancer Biomark; 2017; 18(3):297-303. PubMed ID: 27983538
[TBL] [Abstract][Full Text] [Related]
46. Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology.
Vashi PG; Trukova K; Lammersfeld CA; Braun DP; Gupta D
Nutr J; 2010 Nov; 9():60. PubMed ID: 21092237
[TBL] [Abstract][Full Text] [Related]
47. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Ko AH; Dito E; Schillinger B; Venook AP; Xu Z; Bergsland EK; Wong D; Scott J; Hwang J; Tempero MA
Invest New Drugs; 2008 Oct; 26(5):463-71. PubMed ID: 18379729
[TBL] [Abstract][Full Text] [Related]
48. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
[TBL] [Abstract][Full Text] [Related]
49. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
Astsaturov IA; Meropol NJ; Alpaugh RK; Burtness BA; Cheng JD; McLaughlin S; Rogatko A; Xu Z; Watson JC; Weiner LM; Cohen SJ
Am J Clin Oncol; 2011 Feb; 34(1):70-5. PubMed ID: 20458210
[TBL] [Abstract][Full Text] [Related]
50. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Cunningham D; Chau I; Stocken DD; Valle JW; Smith D; Steward W; Harper PG; Dunn J; Tudur-Smith C; West J; Falk S; Crellin A; Adab F; Thompson J; Leonard P; Ostrowski J; Eatock M; Scheithauer W; Herrmann R; Neoptolemos JP
J Clin Oncol; 2009 Nov; 27(33):5513-8. PubMed ID: 19858379
[TBL] [Abstract][Full Text] [Related]
51. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.
Savoie MB; Paciorek A; Zhang L; Van Blarigan EL; Sommovilla N; Abrams D; Atreya CE; Bergsland EK; Chern H; Kelley RK; Ko A; Laffan A; Sarin A; Varma MG; Venook AP; Van Loon K
J Gastrointest Cancer; 2019 Dec; 50(4):769-779. PubMed ID: 30058032
[TBL] [Abstract][Full Text] [Related]
52. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer.
Rasmussen LS; Yilmaz MK; Falkmer UG; Poulsen LØ; Bøgsted M; Christensen HS; Bojesen SE; Jensen BV; Chen IM; Johansen AZ; Hansen CP; Hasselby JP; Holländer N; Nielsen SE; Andersen F; Bjerregaard JK; Pfeiffer P; Johansen JS
Eur J Cancer; 2021 Feb; 144():72-80. PubMed ID: 33341448
[TBL] [Abstract][Full Text] [Related]
53. Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD.
Navaneethan SD; Schold JD; Arrigain S; Jolly SE; Jain A; Schreiber MJ; Simon JF; Srinivas TR; Nally JV
Am J Kidney Dis; 2011 Oct; 58(4):536-43. PubMed ID: 21816525
[TBL] [Abstract][Full Text] [Related]
54. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
[TBL] [Abstract][Full Text] [Related]
55. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
56. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
Ottaiano A; Capozzi M; De Divitiis C; De Stefano A; Botti G; Avallone A; Tafuto S
Acta Oncol; 2017 Mar; 56(3):377-383. PubMed ID: 28256961
[TBL] [Abstract][Full Text] [Related]
57. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Khan K; Cunningham D; Peckitt C; Barton S; Tait D; Hawkins M; Watkins D; Starling N; Rao S; Begum R; Thomas J; Oates J; Guzzardo V; Fassan M; Braconi C; Chau I
Oncotarget; 2016 Mar; 7(11):12672-81. PubMed ID: 26862857
[TBL] [Abstract][Full Text] [Related]
58. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
Cascinu S; Berardi R; Labianca R; Siena S; Falcone A; Aitini E; Barni S; Di Costanzo F; Dapretto E; Tonini G; Pierantoni C; Artale S; Rota S; Floriani I; Scartozzi M; Zaniboni A;
Lancet Oncol; 2008 Jan; 9(1):39-44. PubMed ID: 18077217
[TBL] [Abstract][Full Text] [Related]
59. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Hammel P; Fabienne P; Mineur L; Metges JP; Andre T; De La Fouchardiere C; Louvet C; El Hajbi F; Faroux R; Guimbaud R; Tougeron D; Bouche O; Lecomte T; Rebischung C; Tournigand C; Cros J; Kay R; Hamm A; Gupta A; Bachet JB; El Hariry I
Eur J Cancer; 2020 Jan; 124():91-101. PubMed ID: 31760314
[TBL] [Abstract][Full Text] [Related]
60. Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors.
Sheean P; Arroyo C; Woo J; Schiffer L; Stolley M
J Acad Nutr Diet; 2018 Apr; 118(4):568-577. PubMed ID: 29305131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
